Anti-psgl-1 antibodies and uses thereof

Abstract

Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.

1 . A monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:
 (i) a variable light (“VL”) chain region comprising the amino acid sequence of SEQ ID NO: 3;   (ii) a heavy chain comprising variable heavy (“VH”) chain region comprising the amino acid sequence of SEQ ID NO: 4; and   (iii) a human IgG4 constant region which contains a Serine to Proline substitution at amino acid 228 of the heavy chain numbered according to the EU index.   
     
     
         2 . A monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:
 (i) a light chain comprising the amino acid sequence of SEQ ID NO: 1; and   (ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2.   
     
     
         3 . A monoclonal antibody which immunospecifically binds to human PSGL-1, comprising:
 (i) a heavy chain consisting of SEQ ID NO: 2; and   (ii) a light chain consisting of SEQ ID NO: 1.   
     
     
         4 . A monoclonal antibody which immunospecifically binds to human PSGL-1 and comprises a heavy chain comprising:
 (i) a VH chain region comprising SEQ ID NOs: 8, 9, and 10; and   (ii) a human IgG4 heavy chain constant region containing a Serine to Proline amino acid substitution at amino acid 228 of the heavy chain numbered according to the EU index.   
     
     
         5 . The monoclonal antibody of  claim 4 , wherein the monoclonal antibody further comprises a light chain comprising a VL chain region comprising SEQ ID NOs: 5, 6, and 7. 
     
     
         6 . The monoclonal antibody of  claim 1 , wherein the antibody is purified. 
     
     
         7 . A pharmaceutical composition comprising the monoclonal antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the monoclonal antibody is purified. 
     
     
         9 . An antibody heavy chain comprising SEQ ID NO: 2. 
     
     
         10 . A kit comprising a first container containing the monoclonal antibody of  claim 1 . 
     
     
         11 . An injection device containing the monoclonal antibody of  claim 1 . 
     
     
         12 . The injection device of  claim 11 , wherein the injection device is a syringe. 
     
     
         13 . A method for treating an inflammatory disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of the monoclonal antibody of  claim 1 . 
     
     
         14 . A method for treating an inflammatory disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of  claim 7 . 
     
     
         15 . The method of  claim 13 , wherein the inflammatory disorder is an autoimmune disease. 
     
     
         16 . The method of  claim 13 , wherein the inflammatory disorder is: psoriasis, plaque psoriasis, chronic plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, or diabetes. 
     
     
         17 . The monoclonal antibody of  claim 2 , wherein the antibody is purified. 
     
     
         18 . A pharmaceutical composition comprising the monoclonal antibody of  claim 2  and a pharmaceutically acceptable carrier. 
     
     
         19 . The monoclonal antibody of  claim 4 , wherein the antibody is purified. 
     
     
         20 . A pharmaceutical composition comprising the monoclonal antibody of  claim 4  and a pharmaceutically acceptable carrier.